VeriSIM Life

VeriSIM Life is a San Francisco-based drug development technology company that applies artificial intelligence, machine learning and computational simulation to preclinical translational research. Its core product, BIOiSIM, is described as a decision engine that combines chemical and biological modeling with AI/ML methods and data to produce a Translational Index, a measure intended to predict how a drug candidate will affect patients and to help pharmaceutical organizations prioritize portfolios and reduce R&D risk. The company reports platform characteristics including an inferential search space of roughly 1 billion drug-like compounds, capacity for approximately 800 billion simulation scenarios, about 1.5 million validation simulations, and average prediction accuracy of 83% from structure-only inputs.

A second product, AtlasGEN Novel Drug Designer, uses generative AI and deep learning across a search library of more than 1 trillion compounds to generate target-engaging molecular hits and simultaneously score them for translatability using the Translational Index. The company states AtlasGEN predicts protein-ligand binding affinity by combining geometric conformer analysis with machine learning trained on experimental data, and characterizes this as 72% more efficient than molecular docking-based approaches.

Beyond software and services, VeriSIM Life carries its own therapeutic pipeline spanning conditions such as pulmonary arterial hypertension, substance use disorder and difficult oncology indications. PulmoSIM Therapeutics, a wholly owned brand of VeriSIM Life, identifies licensable candidates for preclinical translation and out-licensing to commercialization partners.

Founding story

VeriSIM was founded in 2017 by Dr. Jo Varshney, a veterinarian and PhD scientist, together with a cross-functional team of pharmaceutical scientists, software engineers and AI/ML and simulation experts. Varshney has said she moved into translational medicine early in her career and identified gaps in how AI, machine learning and statistical data were applied to reduce timelines and risk, as well as the limitations of animal models, noting that diseases cured in mice have not translated to human cures. Dr. Vivek Gupta is listed as scientific co-founder.

Business model

VeriSIM Life sells AI-driven drug development services and platform access to pharmaceutical companies, biotechs, and academic and research institutions, and also enters risk-sharing collaborations to co-develop promising drug candidates. In parallel it develops internal assets through its PulmoSIM Therapeutics brand, which identifies licensable candidates for preclinical translation and out-licensing to commercialization partners.

Revenue comes from platform-based drug development services and insights delivered to pharma, biotech and academic customers, supplemented by risk-sharing development partnerships and the out-licensing of internally advanced candidates. The founder has described the company as revenue-generating with significant pharmaceutical collaborations.

Traction

The company reports assets in its pipeline accelerated by BIOiSIM, covering pulmonary arterial hypertension, substance use disorder and complex oncology indications, and states it works with pharmaceutical, biotech and academic customers. Its founder has publicly described the company as a revenue-generating business with significant pharmaceutical company collaborations and characterized 2023 as a record year. Institutional engagement includes a research collaboration with the FDA/NCTR under a Material Transfer Agreement and a partnership with Clarivate.

Latest developments

PulmoSIM Therapeutics, VeriSIM Life's wholly owned brand, received a U.S. Notice of Allowance for a foundational patent covering PT001. VeriSIM Life also formalized a research collaboration with the FDA's National Center for Toxicological Research through a Material Transfer Agreement focused on mechanistic AI for drug development, and on August 21, 2026 was named a finalist in the 2026 CPHI Awards Innovation Catalyst category.